EDElisabeth Diot

Elisabeth Diot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisabeth Diot has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lingual Raynaud’s Phenomenon: A Case Series and Literature Review

    by Marie Morard, Nicolas Brebion, Marc Lambert, Elisabeth Diot, Bertrand Lioger, Jean-Manuel Kubina, Christian Agard, Olivier Espitia

    Background: Raynaud’s phenomenon of the tongue is a rare manifestation that may be associated with systemic diseases. The clinical manifestations, etiologies and management of this condition are poorly described. Methods: We report 10 cases of lingual Raynaud’s phenomenon (LRP) and 26 cases from a structured literature review. Results: In 38.8% of cases, the LRP occurred in the context of a previously diagnosed systemic sclerosis; 16.6% followed radiotherapy for head and neck cancer; and 27.8% of patients presented with an idiopathic-like form. The manifestations classically included a syncopal phase (91.7%) associated with hypoesthesia (88.9%) and possible dysarthria (52.8%). Atypical presentations with a primary cyanotic phase were also observed, particularly in the context of vasculitis, notably cryoglobulinemic vasculitis (four patients). Active smoking was a significant triggering factor in idiopathic forms (60%). Across all patients—both primary and secondary forms—the most common triggering factor was cold exposure (75%). Vasodilator use showed good efficacy and should be considered for all highly symptomatic patients. Conclusions: In summary, LRP is more frequently associated with systemic sclerosis, manifesting as blanching of the tongue associated with hypoesthesia and dysarthria in more than half of cases. Vasodilators may reduce symptoms. Larger studies are needed to confirm these findings.

  • Open Access

    High Prevalence of the Lung Ultrasound Interstitial Syndrome in Systemic Sclerosis Patients with Normal HRCT and Lung Function—A Pilot Study

    by Camille Mercier, Benjamin Thoreau, Thomas Flament, Sylvie Legué, Arthur Pearson, Stephanie Jobard, Sylvain Marchand-Adam, Laurent Plantier, Elisabeth Diot

    Objective: High-resolution computed tomography (HRCT) may lack sensitivity for the early detection of interstitial lung disease associated with systemic sclerosis (SSc-ILD). Lung ultrasound is an emerging technique for the diagnosis of SSc-ILD. This cross-sectional study aimed to describe the prevalence of ultrasound interstitial syndrome in SSc patients with normal HRCT and pulmonary function tests (PFT). Methods: Thirty SSc patients with normal HRCT, FVC > 80% predicted and DLCO > 70% predicted were included. Echocardiography and PFT including impulse oscillometry and cardiopulmonary exercise testing were performed. Lung ultrasound was analyzed by two blinded operators. Patients were classified into two groups, according to the presence or absence of ultrasound interstitial syndrome, defined as the sum of B-lines in all thoracic areas ≥10 and/or pleural line thickness >3 mm on at least one thoracic area and/or a pleural line irregularity score >16%. Results: Ultrasound interstitial syndrome was present in 12 patients (40%). Inter-reader agreement for the diagnosis of ultrasound interstitial syndrome defined by the Kappa coefficient was 0.93 (95%CI 0.79–1.00). Patients with ultrasound interstitial syndrome were younger (37 years vs. 53 years, p = 0.009), more often had pitting scars (n = 7/12 vs. 3/18, p = 0.045) and had lower FVC (102 vs. 110% pred, p = 0.009), TLC (114 vs. 122% pred, p = 0.042) and low-frequency respiratory system reactance (Xrs5 Z-score 0.16 vs. 1.02, p = 0.018), while pulmonary gas exchange was similar. Conclusions: Ultrasound interstitial syndrome was detected in 12/30 SSc patients with normal HRCT and PFT. Patients with ultrasound interstitial syndrome had differences in lung function consistent with reduced respiratory compliance, suggesting minimal and/or early suspected SSc-ILD.


  • Atteinte des vaisseaux de gros calibre au cours des vascularites à ANCA : une étude multicentrique cas-témoin

    by V. Monghal, X. Puéchal, P. Smets, F. Vandergheynst, M. Michel, E. Diot, Y. Ramdani, T. Moulinet, R. Dhôte, A. Hautcoeur, et al.

  • REUSSI protocole : RElevance of UltraSonography for assessing Salivary gland Involvement in systemic sclerosis (SSc), results from a multicenter cross-sectional pilot study

    by F. Zimmermann, F. Robin, C. Cazalets, R. Garlantézec, S. Jousse-Joulin, E. Diot, A. Bleuzen, C. De Moreuil, N. Belhomme, G. Coiffier, et al.

  • Étude BRASS : évaluation de l’efficacité de la toxine botulinique dans le phénomène Raynaud secondaire à la sclérodermie systémique

    by Patricia Senet, Hervé Maillard, Elisabeth Diot, Isabelle Lazareth, Sophie Blaise, Jean-Philippe Arnault, Marc-Antoine Pistorius, Carine Boulon, Olivier Cogrel, Ursula Warzocha, et al.

  • Open Access

    OP0295 GR2 MULTICENTRIC PROSPECTIVE FRENCH STUDY'S RESULTS: DAMAGE BUT NOT REMISSION AT FIRST TRIMESTER PREDICTS ADVERSE PREGNANCY OUTCOME IN LUPUS PREGNANCIES

    by M. Larosa, V. Le Guern, G. Guettrot Imbert, E. Lazaro, N. Morel, N. Abisror Jeannin, C. Morati-Hafsaoui, P. Orquevaux, E. Diot, F. Sarrot-Reynauld, et al.

    Background: Active Systemic Lupus Erythematosus (SLE) during pregnancy is associated with poor obstetrical outcome but it is still not clear if remission, lupus low disease activity state (LLDAS) is the best target to achieve at conception. Besides, the effect of damage on pregnancy outcome has not been studied. Objectives: Our aim was to determine the 1st trimester risk factors for adverse pregnancy outcome (APO). Methods: Inclusion criteria were: 1) women≥18 years enrolled in the prospective GR2 study; 2) with SLE (SLICC criteria); 3) and an ongoing singleton pregnancy at 12 weeks (only 1 pregnancy per patient). We used the following definitions: DORIS1, DORIA2, clinical SLEDAI-2K=0, LLDAS3 (for SLE activity), SFI4 (for flares), and SLICC-damage index5 (for damage). APO included: foetal death, neonatal death, placental insufficiency with premature deliveryrd percentile). Results: 238 patients were included. 234 (98.3%) women were on hydroxychloroquine (HCQ) and 206 (86.5%) had a clinical SLEDAI-2K=0. Regarding pregnancy outcome, 230 (96.6%) patients had a live birth (mean term 37.7 weeks). Thirty-four (14.3%) patients developed at least 1 APO: placental insufficiency (n=22), foetal death (n=7), neonatal death (n=1), and SGA (n=5). Two different regression logistic models were assessed, one for DORIA and one for LLDAS. We found that only SLICC-Damage index and lupus anticoagulant (LAC) were associated with APO (p=0.02, OR 1.8, 95% CI: 1.1-2.9; p=0.001, OR 4.2, 95% CI: 1.8-9.7 respectively for DORIA model; p=0.03, OR 1.7, 95% CI:1.1-2.8; p=0.002, OR 3.7, 95% CI: 1.6-8.7 respectively for LLDAS model). Conclusion: We confirmed that LAC predicts APO. We found for the first time that chronic damage at 1st trimester also predicted APO. No effect of remission/LLDAS was observed in this cohort of patients on HCQ with a stable and well-controlled SLE. References: [1]van Vollenhoven R, et al. ARD 2017. [2]Zen M, et al. ARD. 2015. [3]Franklyn, K. et al. ARD 2016. [4]Petri M, et al. NEJM 2005. [5]Gladman DD, et al. Arthritis Rheum, 1997. Disclosure of Interests: None declared.

  • Gynecologic Vasculitis: Positron Emission Tomography–Computed Tomography Contribution in a Rare Localization of Giant Cell Arteritis

    by Marie-Charlotte Besse, Nived Collercandy, Elisabeth Diot

    We read with great interest the letter entitled “Unusual presentation of giant cell arteritis in 2 patients: uterine involvement,” published in The Journal of Rheumatology 1. We have observed a case of ovarian involvement of giant cell arteritis (GCA) whose characteristics allow us to reinforce some key messages regarding the investigation of inflammatory disorders. A 67-year-old female (who has given her written informed consent to … Address correspondence to Dr. E. Diot, Service de Médecine Interne, CHRU de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France. E-mail: elisabeth.diot{at}univ-tours.fr


  • Open Access

    Letter to the Editor: Central Nervous System Involvement in Relapsing Polychondritis, a Rare and Difficult Diagnosis: a Case Report

    by Julien Le Marec, Stéphanie Jobard, Adrien Bigot, Benjamin Terrier, Jean-Philippe Cottier, Frédéric Bastides, Elisabeth Diot

    Le Marec J, et al. J Korean Med Sci. 2017 Jun;32(6):1048-1049. https://doi.org/10.3346/jkms.2017.32.6.1048


  • THU0237 Impact of recurrent ischemic digital ulcers on hand disability in systemic sclerosis –

    by L. Mouthon, P. Carpentier, A. Khau Van Kien, P. Clerson, H. Maillard, E. Hachulla, C. Frances, E. Diot, C. Lok, E. Puzenat, et al.

    Background Ischemic digital ulcers (DU) are a common complication of systemic sclerosis (SSc). Objectives To evaluate the impact of recurrent DU on hand disability in a prospective, longitudinal, observational study of 24 months. Methods Patients fulfilled ACR or Leroy-Medsger criteria for SSc, experienced at least one DU during the previous year with or without active DU at inclusion, and were eligible for bosentan therapy. Data were collected on SSc, characteristics of past and present DU, modified Rodnan skin score, factors influencing hand function and mobility, disability scores (Cochin hand function scale - CHFS, health assessment questionnaire disability index - HAQ-DI), and quality of life (SF36). Results 217 patients were included between October 2009 and March 2011 in 50 centers. The interim analysis includes 184 patients (128 women). Mean age was 43±15 years at diagnosis of SSc and 53±15 years at inclusion. SSc was diffuse in 44% of patients and Raynaud’s phenomenon (RP) started 14±12 years before inclusion. 11% of patients had pulmonary arterial hypertension. Mean Rodnan score was 14.3±8.8. Time elapsed since the first DU was 6±7 years. In 47% of patients, DU was an early complication (first non-RP sign) and 59% had recurrent DU. Sequelae of DU included loss of substance (62%), autoamputation (8%), and surgical amputation (10%). Complications were infection (8%), gangrene (5%), and osteitis (2%). 54% of patients had at least one active DU at inclusion. In these patients, the mean number of DU was 2.3±1.9; 54% had more than one DU, 37% had both hands involved, and on average 2.2±1.7 fingers were affected. 21% of cases had at least one extended DU (>1cm). Concomitant mechanical ulcers were localized at the dorsal face of fingers (19%), bony reliefs (13%), or calcinosis (1%). DU were painful (visual analogue scale, 6.18±2.56 vs. 2.49±2.56 without DU) and disabling, involving the dominant hand in 72% of patients. DU worsened hand disability (median CHFS, 42 with active DU vs. 26 without DU, pConclusions DU represent an early complication of SSc. They are painful, affecting often multiple fingers and both hands. In patients with SSc, DU are significantly associated with hand disability. Prospective follow-up at two years will allow to further elucidate the specific role that DU episodes play in the disability of these patients. Disclosure of Interest L. Mouthon Consultant for: Lilly, Actelion France, GSK, Pfizer, P. Carpentier Consultant for: Actelion, A. Khau Van Kien: None Declared, P. Clerson: None Declared, H. Maillard: None Declared, E. Hachulla Consultant for: Actelion, GSK, Pfizer, C. Frances: None Declared, E. Diot: None Declared, C. Lok Consultant for: Actelion, E. Puzenat Consultant for: Actelion, A. Sparsa Consultant for: Actelion, A. Bérezné: None Declared, V. Gressin Employee of: Actelion France, M.-A. Richard Consultant for: Actelion